Evidence map›Paper›PMID 23576544›Full record

ArticleJournal of clinical microbiology2013

Use of faropenem as an indicator of carbapenemase activity in the Enterobacteriaceae.

Kathryn M Day, Rachel Pike, Trevor G Winstanley, Clare Lanyon, Stephen P Cummings, Muhammad W Raza, Neil Woodford, John D Perry

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Detection of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021
    Review
  3. Article
  4. The Global Ascendency of OXA-48-Type Carbapenemases.Clinical microbiology reviews · 2019
    Review
  5. Article
  6. Review
  7. Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kathryn M DayMicrobiology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
Rachel Pike
Trevor G Winstanley
Clare Lanyon
Stephen P Cummings
Muhammad W Raza
Neil Woodford
John D Perry
Freeman Hospital · GBNorthumbria University · GBNorthern General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to determine the ability of a disc susceptibility test using faropenem (10 μg) to predict carbapenemase activity in Enterobacteriaceae. A collection of 166 isolates of carbapenemase-producing Enterobacteriaceae (CPE) and 82 isolates of Enterobacteriaceae that produced other β-lactamases was compiled from diverse sources. Disc susceptibility testing was performed using the CLSI/EUCAST methodology with discs of faropenem (10 μg), temocillin (30 μg), and four carbapenems (each 10 μg). A further prospective evaluation of the faropenem disc susceptibility test was performed using 205 consecutive isolates referred to a United Kingdom reference laboratory in parallel with molecular methods for carbapenemase detection. Of 166 isolates of CPE, 99% showed growth up to the edge of a 10-μg faropenem disc compared with only 6% of other β-lactamase producers (sensitivity, 99%; specificity, 94%). A "double zone" around 10-μg faropenem discs was frequently associated with OXA-48 producers. Of the carbapenems, the most useful agent was imipenem, where a zone diameter of ≤ 23 mm as a predictor of carbapenemase activity had a sensitivity of 99% and a specificity of 85%. The presence of no zone of inhibition around a 30-μg temocillin disc was a consistent feature of strains producing OXA-48 carbapenemase. For 205 isolates of Enterobacteriaceae referred to a United Kingdom reference laboratory, growth up to a 10-μg faropenem disc correctly identified 84 of 86 carbapenemase producers (98% sensitivity), with a specificity of 87%. Disc susceptibility testing using faropenem (10 μg) is a simple, convenient, and highly predictive screening test for carbapenemase-producing Enterobacteriaceae.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsEnterobacteriaceaeEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsSensitivity and SpecificityUnited KingdomAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-Lactamscarbapenemasefropenem

Identifiers

PMID23576544
PMCPMC3716051
OpenAlexW2155927569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.